Search company, investor...

R-Pharm

r-pharm.com

Founded Year

2001

Stage

Debt | Alive

Total Raised

$237M

Last Raised

$237M | 7 yrs ago

About R-Pharm

R-Pharm is a Russian private hi-tech pharmaceutical company founded in 2001, employs over 3200 highly qualified specialists, has over 60 branches. R-Pharm operates in Russia and CIS, USA, Germany, Japan, Turkey/MENA and India. The company is involved in R&D, manufacturing, marketing, sales and distribution of innovative pharmaceutical products from a broad number of therapeutic areas in specialty/hospital care.

Headquarters Location

10, Testovskaya st

Moscow, 123317,

Russian Federation

Missing: R-Pharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: R-Pharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing R-Pharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

R-Pharm is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R-Pharm Patents

R-Pharm has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/8/2021

10/25/2022

Antineoplastic drugs, Experimental cancer drugs, Mitotic inhibitors, Copolymers, Topoisomerase inhibitors

Grant

Application Date

1/8/2021

Grant Date

10/25/2022

Title

Related Topics

Antineoplastic drugs, Experimental cancer drugs, Mitotic inhibitors, Copolymers, Topoisomerase inhibitors

Status

Grant

Latest R-Pharm News

South America Human Papillomavirus Vaccine Market Analysis/Forecasts Report 2022-2028 Featuring GlaxoSmithKline, Inovio Pharmaceuticals, Merck & Co, R-Pharm, Sanofi, & Serum Institute of India - ResearchAndMarkets.com

Nov 21, 2022

The South America human papillomavirus (HPV) vaccine market is expected to grow from US$ 173.52 million in 2022 to US$ 239.53 million by 2028; it is estimated to grow at a CAGR of 5.5% from 2022 to 2028. Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE-marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, drug administrations across the region approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers - p16 and Ki-67 - in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers means the person taking the test is at a high risk of getting the disease. Such robust developments in HPV diagnostics tests are likely to reshape the market during the forecast period. With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America human papillomavirus (HPV) vaccine market . The South America human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period. South America Human Papillomavirus (HPV) Vaccine Market Segmentation The quadrivalent HPV vaccine segment would dominate the market in 2022. In terms of dosage, the South America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment would dominate the market in 2022. The 9 to 14 years segment would dominate the market in 2022. In terms of application, the South America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment would dominate the market in 2022. The hospitals segment would dominate the market in 2022. Brazil would dominate the market in 2022. Key Market Dynamics

R-Pharm Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

R-Pharm Rank

R-Pharm Frequently Asked Questions (FAQ)

  • When was R-Pharm founded?

    R-Pharm was founded in 2001.

  • Where is R-Pharm's headquarters?

    R-Pharm's headquarters is located at 10, Testovskaya st, Moscow.

  • What is R-Pharm's latest funding round?

    R-Pharm's latest funding round is Debt.

  • How much did R-Pharm raise?

    R-Pharm raised a total of $237M.

  • Who are the investors of R-Pharm?

    Investors of R-Pharm include Vnesheconombank and OrbiMed Advisors.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.